Infinera (Hangzhou) Biopharmaceutical

Infinera (Hangzhou) Biopharmaceutical is a biotechnology company based in Hangzhou, China, specializing in the development of innovative small molecule therapeutics. The company leverages its proprietary Proteolysis Targeting Chimera (PROTAC) platform to design drugs that induce the degradation of disease-causing proteins, offering a novel approach to treating conditions that are difficult to address with traditional inhibitors. Its primary research focus is currently in oncology, with a lead program targeting the androgen receptor for the treatment of advanced prostate cancer. Infinera aims to bridge the gap between academic discovery and clinical application by advancing a pipeline of high-potential protein degraders.